On October 28, Amicus Therapeutics issued a press release with an update on the progress of our Pompe
program as we received information from the US Food & Drug Administration (FDA) on the regulatory status of
our next-generation therapy for the treatment of late-onset Pompe diseaseA rare genetic disease in which the body cannot properly break down glycogen, leading to buildup that damages muscles and can affect breathing and, in some cases, the heart. More. The entire Pompe community –
from individuals and families to patient advocacy organizations and their leaders – are our valued partners and
we want to share this information with you all within the context of the regulatory activities’ timeline.
Click here for more information